Esperion Therapeutics (ESPR) Return on Assets (2013 - 2026)

Esperion Therapeutics' Return on Assets history runs 14 years deep, the most recent figure standing at 0.0% for Q1 2026.

• Quarterly Return on Assets changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Assets was 0.0% for Q1 2026 at Esperion Therapeutics, up from 0.0% in the prior quarter.
• Across five years, Return on Assets topped out at 0.0% in Q1 2026 and bottomed at 0.01% in Q4 2023.
• A 5-year average of 0.01% and a median of 0.0% in 2025 frame the typical range for Return on Assets.
• Annual changes were most pronounced in 2022 — Return on Assets changed 0 bps — and 2024, when it grew 1 bps.
• Esperion Therapeutics' Return on Assets stood at 0.01% in 2022, then decreased by 19 bps to 0.01% in 2023, then soared by 96 bps to 0.0% in 2024, then tumbled by 47 bps to 0.0% in 2025, then soared by 66 bps to 0.0% in 2026.
• Business Quant data shows ESPR's Return on Assets at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.